BioSpace News Archive

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced sponsorship from the Duchenne Research Fund for an award totaling over $100,000.

Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.

Vonco Products LLC, an industry-leader in the manufacture of liquid-tight medical devices, fluid bags and infection prevention solutions announced that it is responding to the nationwide demand for safe and secure COVID-19 testing by increasing production of 95kPa biohazard transport bags.

The Company has committed to investing an additional $600,000 to acquire 2 million shares, which brings its total equity position to 8.25 million shares.

Recent trends in the global electrophysiology market are driven by the increasing adoption of digital tools for the deployment of various treatments across the medical sector.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that Revitope Oncology is extending its collaboration to develop a systems pharmacology model for Revitope’s dual antigen targeting TwoGATE™ platform for solid tumor indications.

Ongoing COVID-19 disease spread has produced a dramatic demand spurt of personal protective equipment for infection control globally.

Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET.

Pregna International Ltd - a leading women’s healthcare company – has partnered with Dr. Thomas Burke’s Vayu Global Health Initiative to introduce an economical solution to Post-Partum Haemorrhage – one of the leading causes of maternal mortality.

Utah Medical Products, Inc. announces that its Board of Directors approved a quarterly cash dividend of twenty-eight and one-half cents per share of common stock payable on April 2, 2021 to shareholders of record at the close of business on March 17, 2021.